SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await clarity on the FDA's regulatory path for deramiocel, with many focused on the potential for a PDUFA extension following the company's submission of a major BLA amendment. Community sentiment remains highly polarized, pitting retail bulls anticipating a significant squeeze against shorts and skeptics concerned about long-term financial viability and regulatory hurdles.

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending after announcing a massive $13.7 billion six-year GPU cloud services agreement for its Maysville facility, with community members focused on how the deal validates the company's AI infrastructure thesis despite potential dilution and financing requirements. Investors are actively debating the impact of the contract's warrant structure and the potential for a short squeeze given the high short interest and the scale of the long-term revenue opportunity.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing intense community debate as it nears key psychological levels, with bulls eyeing further gains while bears warn of a potential market correction. Investors are closely watching upcoming treasury bond buyback announcements and potential legislative updates for clues on the next move.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors monitor reports that its REGAL Phase 3 trial may have reached the 80th event, a key catalyst for final analysis. While the community is actively debating the credibility of this unconfirmed milestone and potential buyout interest, sentiment remains divided between hopeful bulls and skeptics questioning the trial's official status.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is facing intense downward pressure and negative sentiment despite recent partnerships with Momenta and XHEART, as investors express mounting frustration over delayed product timelines, insider selling, and lackluster share price performance. The community remains deeply divided between long-term holders citing the company's QNX safety-certified foundation as an undervalued infrastructure asset and skeptics who view leadership as unable to translate partnerships into sustainable revenue.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is seeing increased retail interest following the reveal of its humanoid robot production goals and the upcoming launch of the MONA L03 model, as investors debate whether the company should be valued primarily as an EV manufacturer or an emerging leader in physical AI. While some remain wary of broader market pressure on Chinese equities, many are highlighting the firm's technological stack and software partnerships as potential long-term catalysts.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors brace for the chipmaker's upcoming earnings report, with sentiment currently weighed down by reports of impending hardware price hikes and persistent debates over whether AI-driven revenue growth is sustainable. The community remains deeply divided, with many traders preparing for traditional post-earnings volatility while others view any pre-report weakness as a buying opportunity given the company's central role in AI infrastructure.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba shares are under pressure as investors weigh the impact of a $10.2 billion capital raise aimed at funding AI infrastructure against concerns over share dilution and increased spending. While the move has triggered short-term volatility, the community remains actively divided, with many retail traders maintaining a bullish stance due to the company's aggressive AI product expansion and cloud growth prospects.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is surging as Bitcoin nears $80k and the company announces a new $1.59 billion USD cash pool to enhance its treasury flexibility. The community is actively debating the stock's performance relative to Bitcoin, with many expressing bullish sentiment on potential for a short squeeze while others highlight ongoing concerns regarding share dilution.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio shares are seeing significant volatility following a regulatory setback for its RGX-121 gene therapy, which remains under a clinical hold and faces a BLA rejection that the company is actively appealing. While the stock has faced downward pressure, the community remains divided, with many retail investors viewing the selloff as an overreaction and pointing to the strength of its Duchenne and retinal disease pipeline as a reason to maintain a long-term bullish outlook.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H.C. Wainwright, on 2/19, reiterated $DRUG Buy-$85 and said &quot;we view Bright Minds as a differentiated player in the serotonergic epilepsy landscape with BMB-101 positioned as a potential best-in-class therapy pending Phase 2 data in 2Q25.&quot; 
$HLBBF - $LBPH  
 
H.C. Wainwright said in its note to investors:

Derrick Stephens

Cain Phan

Trader2

Alejandra Reid

Piper Sandler🏁 $DRUG Overweight-$93, says &#39;we are initiating coverage on Bright Minds Biosciences with an OW rating and $93 PT.&#39; 
$LBPH $HLBBF  
 
&quot;We believe its lead asset, BMB-101, is a differentiated G-protein biased 5-HT2C agonist positioned to drive sustained efficacy in drug-resistant epilepsies with clean safety. 
 
In our view, the recent $2.6B acquisition of Longboard Pharmaceuticals (by H. Lundbeck A/S, not covered) validates the 5-HT2C agonist MoA value proposition with positive bexicaserin Ph1b/2a PACIFIC data driving strategic interest. As such, we see BMB-101 as a more potent 5-HT2C agonist compared to bexicaserin with no ß-arrestin recruitment. 
 
Thus, we expect 2H25 topline from open-label Ph2 BREAKTHROUGH in n =~ 20 absence epilepsy or DEE patients to drive share movement and potentially close the ~$2.35B valuation gap in tandem with a growing portfolio of 5-HT assets.&quot;

StockTwits Web

Bright Minds Biosciences Inc

Longboard Pharmaceuticals Inc

H. Lundbeck AS - Ordinary Shares - Class B

Quantumup

 Buy-$85 and said "we view Bright Minds as a differentiated player in the serotonergic epilepsy landscape with BMB-101 positioned as a potential best-in-class therapy pending Phase 2 data in 2Q25." 


  
 
H.C. Wainwright said in its note to investors: